ReviewNaunyn-Schmiedeberg's archives of pharmacology2026

Breaking resistance barriers: ensartinib as a milestone in anaplastic lymphoma kinase-driven non-small cell lung cancer therapy.

Lohitha Gumma et al.PubMed ↗Publisher ↗

No numbers read from the abstract.